CymitQuimica ha oltre 25 partner, tra i quali spicca il fornitore TargetMol

Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is a substrate for the WNV NS2B-NS3 protease. It is utilized in the development of selective inhibitors for peptide substrates of the WNV NS2B-NS3 protease.

<p>Aβ1-14-εK-KKK-MvF5 Th (UB311 immunogen I) is a biologically active peptide and one of the Aβ1–14 targeting peptides (B-cell epitope) used in UB-311.</p>

Delta-hemolysin (Delta-lysin) TFA is a peptide composed of 26 amino acids, produced by staphylococci as a hemolytic peptide. It may slightly disrupt cell membranes or lead to cell lysis and serves as a model for studying peptide-membrane interactions. Its activity against bacteria is relatively weak.

<p>Phospho-L-arginine is a derivative of arginine.</p>

Myristoylated ARF6 (2-13) inhibits the MyD88–ARNO–ARF6 signaling axis by inactivating ARF6.

M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) TFA is a bioactive peptide that functions as an agonist for NOD1/2.

GVSKYG-PEG2-azide (TFA) is a click chemistry reagent featuring an azide group that can participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. It can also undergo strain-promoted azide-alkyne cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

Relaxin H3 (human) (TFA) is a relaxin peptide that exerts antifibrotic effects through the RXFP1 receptor.

Palmitoyl tetrapeptide-20 (PTP20) TFA is a biomimetic peptide and acts as an agonist of α-MSH. It protects follicular melanocytes by boosting catalase expression and activating melanogenesis.

PKH is a TLR4 antagonist, and it is a new tripeptide derived from Akkermansia muciniphila. PKH reduces inflammation-related cell activation and the overproduction of pro-inflammatory factors induced by sepsis.

GVSKYG-PEG2-azide (hydrochloride) is a click chemistry reagent containing an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules possessing alkyne groups. Molecules with DBCO or BCN groups may also participate in strain-promoted alkyne-azide cycloaddition (SPAAC).

TAT-P110 is a peptide inhibitor that disrupts the interaction between Drp1 and Fis1, effectively reducing pathological changes in various models of neurodegenerative diseases, ischemia, and sepsis without impairing the physiological function of Drp1.

<p>DOTA-ubiquicidin (29-41) is a derivative of an antimicrobial peptide fragment employed for synthesizing [68Ga]Ga-DOTA-Ubiquicidin29-41, which is subsequently utilized in PET/CT imaging of infection processes. Additionally, DOTA-ubiquicidin (29-41) is applicable in the synthesis and research of radiopharmaceuticals known as radionuclide conjugates (RDC).</p>

SPN009 (Sequence 3) is a GLP-1 receptor (GLP-1 Receptor) agonist, with an EC50 of 2.84 nM, and improves type 2 diabetes in DB/DB mouse models.

Fusionglycoprotein92-106 is a peptide derived from the respiratory syncytial virus (RSV) fusion protein. It functions as an MHC class I-restricted cytotoxic T lymphocyte (CTL) epitope, with all 15 amino acids effectively recognized by CTLs.

<p>Kiss2 peptide functions as a positive regulator of reproductive behavior. In COS-7 cells, it binds to its homologous G-protein coupled receptor Kiss2R (GPR54), activating the PKA and PKC signaling pathways through Gas and Gaq proteins. This enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc).</p>

<p>S1H is an analog of human growth hormone (hGH) and acts as an antagonist to the human growth hormone receptor (hGHR). It inhibits the interaction between hGH and hGHR and prevents the phosphorylation of STAT5 in cells treated with hGH.</p>

<p>Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse). The amidation of the C-terminal tyrosine in Neuropeptide Y is essential for its function, while the non-amidated form cannot initiate G-protein signaling.</p>

<p>GUB03385 is a long-acting PrRP31 analogue and an effective dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM), with anti-obesity properties.</p>

<p>OP-145 is a derivative of the antimicrobial peptide LL-37, known for its antibacterial properties against multiple MRSA strains. This compound is applicable in studies on chronic suppurative otitis media.</p>

NOTA-Pep-1L specifically targets the IL13RA2 receptor and is utilized for tumor imaging. Additionally, it is employed in the synthesis and research of radiolabeled conjugates (RDC).

CXCL8 (54-72) is a C-terminal peptide segment of the chemokine CXCL8. This peptide features a long, highly positively charged C-terminal region that interacts with the negative charges on glycosaminoglycans (GAG) to facilitate binding. CXCL8 (54-72) inhibits neutrophil adhesion and migration, as well as adhesion to endothelial cells. It is useful in studying the role of chemokines in inflammatory responses.

155H1 (Compound 11) is a stapled peptide that covalently binds to hMcl1 (172-323) with an IC50 of 18 nM.

GLP-1R/GIPR agonist-1 is a dual receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It mimics the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while suppressing glucagon release, thus lowering blood sugar. This compound is used in research related to metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

<p>Palm11-PrRP31 is a lipid-modified analog of the endogenous appetite-suppressing neuropeptide (PrRP). It functions as a potent dual agonist for GPR10 (EC50 = 39 pM) and NPFF-R2. By mimicking the natural activity of PrRP, palm11-PrRP31 binds to these receptors to reduce food intake. It has potential applications as an anti-obesity agent and is useful in studying neuropeptide and receptor interactions.</p>

VGN50 is a bioactive molecule that mimics the function of K-Rta, capable of downregulating MYC-mediated gene transcription. VGN50 exhibits antitumor activity.

palm-PrRP31 is a potent dual agonist for GPR10 (EC50=72 pM) and NPFF-R2. It activates downstream signaling pathways by binding to GPR10 and NPFF-R2 receptors, leading to reduced appetite and increased energy expenditure. palm-PrRP31 can be utilized to investigate its mechanism of action in the nervous system, thereby elucidating the complex biological processes involved in the regulation of appetite and energy expenditure.

DP50 is a bifunctional compound containing both an opioid receptor agonist (MOP) and a neuropeptide FF receptor (NPFFR) antagonist. It can be utilized in studies related to analgesia.

<p>RCP168 is a highly selective and potent CXCR4 receptor antagonist with an IC50 of 5 nM. It exhibits superior capacity to inhibit HIV-1 (Human Immunodeficiency Virus type 1) from entering host cells via the CXCR4 receptor compared to natural chemokines. RCP168 suppresses HIV-1 infection by blocking viral binding sites or inducing receptor internalization. It can be utilized in research to study interactions between the CXCR4 receptor and other chemokine receptors.</p>

<p>LDV-FITC TFA is a fluorescent peptide, specifically an FITC-conjugated LDV peptide. This compound binds to the α4β1 integrin with high affinity, displaying a Kd of 0.3 nM in the presence of Mn2+ and 12 nM in its absence, when binding to U937 cells. LDV-FITC TFA is useful for assessing α4β1 integrin affinity.</p>

H2-D b restricted epitopesVSVNucleoprotein (52-59) is a nonapeptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). It binds to MHC class I molecules to present itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs) that recognize and destroy cells expressing the corresponding antigen. This epitope is instrumental in the development of CTL vaccines against the Ebola virus.

AADvac 1 TFA is an active tau peptide vaccine utilized in Alzheimer's disease research. It is formed by conjugating the regulatory peptide 294KDNIKHVPGGGS305, which drives tau oligomerization, with keyhole limpet hemocyanin (KLH), and is formulated with aluminum hydroxide.

RAG8 peptide is an antagonist of protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation and reduces thrombosis without altering hemostasis or increasing bleeding risk. It is applicable in atherosclerosis research.

Globomycin derivative G2A (Compound G2A) is an inhibitor of lipoprotein signal peptidase II (LspA), with an IC50 of 604 nM. It exhibits inhibitory activity against E. coli, P. aeruginosa, and A. baumannii, displaying minimum inhibitory concentrations (MIC) ranging from 12.5 to 32 μg/mL.

<p>The M133 peptide is a coronavirus-specific CD4 T cell epitope. In mice infected with the neurotropic coronavirus (strain JHM of mouse hepatitis virus), the M133 peptide demonstrates immunodominance. It activates CD4 T cells by forming an MHC/peptide complex through binding with MHC II molecules, which is recognized by specific TCRs.</p>

<p>OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.</p>

BCOR(498-514), biotinylated, is the smallest BCL6 binding domain with a KD of 1.32 µM. It can block BCL6-mediated transcriptional repression and induce cell death in lymphoma cells.

<p>AcrAP2 is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). It exhibits inhibitory effects on Gram-positive bacteria and yeast while generally showing no activity against Gram-negative bacteria. The cationic-enhanced analogue of AcrAP2 (AcrAP2a) has demonstrated significant antiproliferative effects on certain human cancer cell lines at low concentrations. AcrAP2 holds potential for research in antibacterial and antitumor applications.</p>

CPN-351 (compound 9a) is a pentapeptide that acts as a selective antagonist for human NMUR1, with a pA2 value of 7.35. It exhibits ten times greater antagonistic activity toward human NMUR1 compared to NMUR2. CPN-351 is applicable in inflammation research.

<p>HG1 Toxin is a peptide found in the venom of the scorpion Heterometrus fulvipes, known for its ability to inhibit the potassium channel Kv1.3 (potassium channel Kv1.3). Additionally, HG1 Toxin exhibits trypsin inhibitory activity (Ki=107 nM), making it useful for research into autoimmune diseases.</p>

<p>Cyclic AC253 is an amylin receptor antagonist with an IC50 of 0.3 μM. It offers neuroprotective effects against Aβ toxicity and mitigates Aβ-induced impairments in hippocampal long-term potentiation. Additionally, Cyclic AC253 is capable of penetrating the blood-brain barrier.</p>

Semaglutide (FITC-labeled Semaglutide) is a long-acting analog of human glucagon-like peptide-1, functioning as an agonist of the GLP-1 receptor. It shows potential for research related to type 2 diabetes.

BRC4 peptide, a specific segment of the BRCA2 protein, interacts with the RAD51 protein to assist in repairing broken DNA strands. It is useful in studying DNA repair mechanisms and the development of cancer.

Apo A-I mimetic 5A peptide is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). It facilitates the efflux of cholesterol from inside cells, helping to reduce intracellular cholesterol accumulation. Additionally, Apo A-I mimetic 5A peptide exhibits anti-inflammatory properties, lowering inflammatory markers in blood and tissues. This peptide is used in cardiovascular disease research.

Tet1peptide is a neuron-specific ligand for GT1B ganglioside. It can serve as a ligand for the targeted delivery of functionalized polymers.